Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 300 IN PLASTIC CONTAINER versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 300 IN PLASTIC CONTAINER versus RENOVIST II.
IOPAMIDOL-300 IN PLASTIC CONTAINER vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a non-ionic, low-osmolality iodinated contrast agent that increases the radiopacity of vascular structures and tissues by attenuating X-rays. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Intravenous administration: 1-2 mL/kg (300-600 mg iodine/kg) for contrast imaging; maximum 200 mL per procedure.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Approximately 2 hours in patients with normal renal function (GFR >90 mL/min). Prolonged in renal impairment (up to 30 hours or more in severe disease).
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal elimination is negligible (<1%).
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent